Elsevier

The Lancet

Volume 318, Issues 8260–8261, 26 December 1981, Pages 1382-1384
The Lancet

ANTI-PLATELET ACTIVITY OF BETA-ADRENERGIC ANTAGONISTS: INHIBITION OF THROMBOXANE SYNTHESIS AND PLATELET AGGREGATION IN PATIENTS RECEIVING LONG-TERM PROPRANOLOL TREATMENT

https://doi.org/10.1016/S0140-6736(81)92800-2Get rights and content

Abstract

Treatment of hypertensive patients with dl-propranolol (640 mg/day) significantly inhibited thromboxane synthesis by their platelets and platelet aggregation induced by thrombin or arachidonic acid. The effects were dose-related and were also caused by the stereoisomer, d-propranolol (640 mg/day), which has very little beta-blocking activity. These findings suggest that the cardioprotective effects of propranolol may be due partly to this anti-platelet activity, to a reduction in thromboxane-induced coronary-artery vasoconstriction, or to both. d-Propranolol treatment may be particularly useful, since this isomer provides similar benefits without causing pronounced beta-adrenergic blockade.

References (16)

  • Rm Norris et al.

    Protective effect of propranolol in threatened myocardial infarction

    Lancet

    (1978)
  • Bb Weksler et al.

    Effect of propranolol on platelet function

    Blood

    (1977)
  • RM. Graham

    The physiology and pharmacology of alpha- and beta-blockade

    Cardiovasc Med

    (1981)
  • Ka Reimer et al.

    Reduction by propranolol of myocardial necrosis following temporary coronary artery occlusion in dogs

    Circ Res

    (1973)
  • Wb Campbell, Ks Callahan, Ar Johnson, PD. Hirsh, Mechanism of the antiplatelet activity of the β-adrenergic...
  • M. Hamberg et al.

    Thromboxanes: a new group of biologically active compounds derived from prostaglandin endoperoxides

    Proc Natl Acad Sci U.S.A.

    (1975)
  • Gvr. Born

    Aggregation of blood platelets by adenosine diphosphate and its reversal

    Nature

    (1962)
There are more references available in the full text version of this article.

Cited by (105)

  • β-blockers reduce the incidence of clinical restenosis: Prospective study of 4840 patients undergoing percutaneous coronary revascularization

    2003, American Heart Journal
    Citation Excerpt :

    β-Blockers have antiplatelet effects that should reduce platelet aggregation and deposition on the arterial wall.23-25 They also decrease platelet production and release of thromboxane A2.9,26 β-Blockers lower heart rate, reducing mean blood velocity and shear stress on the arterial wall, reducing adverse remodeling resulting from intimal hyperplasia.23,27,28

  • Effects of prior beta-blocker therapy on clinical outcomes after primary coronary angioplasty for acute myocardial infarction

    2003, American Journal of Cardiology
    Citation Excerpt :

    Beta blockers reduce myocardial oxygen demand,17 improve infarct zone motion, and reduce noninfarct zone motion,18 contributing to reduced infarct size and improved regional myocardial function. In experimental studies, β blockers redistribute blood flow to ischemic subendocardial regions19,20; further, β blockers inhibit platelet aggregation and thromboxane synthesis in vitro and in vivo.21,22 These properties could explain the higher incidence of spontaneous recanalization in β patients in our study, as well as their lower incidence of death from reinfarction, shock, or heart failure.

  • Stress and the inflammatory response: A review of neurogenic inflammation

    2002, Brain, Behavior, and Immunity
    Citation Excerpt :

    Administration of E can cause similar changes in blood coagulation and fibrinolytic activity, which supports the functional role of stress in hemostasis (Jern et al., 1989; Raikkonen et al., 1996b). These changes are likely to combine with the platelet activating effect of E and NE, and the SNS induced production of thromboxane A2 which promotes thrombosis (Campbell, Callahan, Johnson, & Graham, 1981). Sympathetic activation also decreases prostacyclin synthesis in endothelial cells; prostacyclin is a potent vasodilator, has platelet antiaggregatability effects and may inhibit the growth of fibrous tissue and the intimal accumulation of lipids (Kaplan & Manuck, 1994).

  • Stress, inflammation and cardiovascular disease

    2002, Journal of Psychosomatic Research
View all citing articles on Scopus
View full text